Green Mountain Logic will unveil LabPAS/CT Version 2.5 at the DIA Annual Meeting.
Philadelphia, June 18–21, booth # 1520-Version 2.5 deploys PDAs on clinic floors to scan patient and collection vessel barcodes, eliminating the potential for errors. It provides real time electronic data entry for collection times, comments, dosing, vital signs and adverse events. LabPAS/CT 2.5 also allows integration with document management systems and with biometric systems for positive subject ID.
LabPAS/CT uses a Web interface and intuitive navigation and is the most scalable, configurable and customizable workflow and sample management solution on the market today. Through the innovative use of barcode scanning it eliminates errors, tracks samples, increases throughput, and supports compliance. In addition, sample collection and dosing are scheduled and tracked according to trial protocols. LabPAS/CT supports compliance with FDA 21 CFR Part 11, GCP and GLP, and also empowers study managers to rapidly alter workflow and schedules as protocols change, by simply dragging and dropping items on their computer screen. It was developed under Green Mountain Logic's design control process, audited and approved by multiple, nationally-recognized pharmaceutical clients. GML is in compliance with FDA guidance for the development of high-risk software systems and for development of Class 2 Medical Devices.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.